# Arbutus Biopharma Corp (ABUS)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001447028 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001447028))
- Full page: https://inspectstocks.com/stocks/abus
- Data as of: price 2026-09-25; newest filing used 2026-08-12; latest fiscal period ended 2026-06-30

## Grade

**C+** on the growth-and-cash rubric, 3 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $181.7M | $23.5M |
| Revenue growing recently | passed | $181.7M | $14.1M |
| Free cash flow positive | failed | -$39.6M |  |
| Free cash flow growing overall | failed | -$39.6M | -$35.9M |
| Free cash flow growing recently | passed | -$39.6M | -$65M |

Business quality (the + / − mark): 5 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 84.2% |  |
| Healthy profit margin | passed | 84.2% |  |
| Strong operating margin | passed | 82.0% |  |
| Good return on equity | passed | 199.9% |  |
| Debt under control | passed | 0.01 |  |
| Turns sales into cash | failed | -21.8% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $181.7M |
| Net income, trailing twelve months | $153.1M |
| Free cash flow, trailing twelve months | -$39.6M |
| Net margin | 84.2% |
| Operating margin | 82.0% |
| Return on equity | 199.9% |
| Debt to equity | 0.01 |
| Diluted EPS, trailing twelve months | $0.79 |
| Share price | $4.85 |
| Market value | $959.6M |
| Price / earnings | 6.1x |
| Price / sales | 5.3x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/abus)
- [Financial statements](https://inspectstocks.com/stocks/abus/financials)
- [Competitors](https://inspectstocks.com/stocks/abus/peers)
- [Earnings](https://inspectstocks.com/stocks/abus/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.